JP2009541236A5 - - Google Patents

Download PDF

Info

Publication number
JP2009541236A5
JP2009541236A5 JP2009515748A JP2009515748A JP2009541236A5 JP 2009541236 A5 JP2009541236 A5 JP 2009541236A5 JP 2009515748 A JP2009515748 A JP 2009515748A JP 2009515748 A JP2009515748 A JP 2009515748A JP 2009541236 A5 JP2009541236 A5 JP 2009541236A5
Authority
JP
Japan
Prior art keywords
branched
moiety
group
phenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2009515748A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009541236A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/005303 external-priority patent/WO2007147529A2/en
Publication of JP2009541236A publication Critical patent/JP2009541236A/ja
Publication of JP2009541236A5 publication Critical patent/JP2009541236A5/ja
Ceased legal-status Critical Current

Links

JP2009515748A 2006-06-20 2007-06-15 組換えウイルスワクチン Ceased JP2009541236A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06360028 2006-06-20
US85296406P 2006-10-20 2006-10-20
PCT/EP2007/005303 WO2007147529A2 (en) 2006-06-20 2007-06-15 Recombinant viral vaccine

Publications (2)

Publication Number Publication Date
JP2009541236A JP2009541236A (ja) 2009-11-26
JP2009541236A5 true JP2009541236A5 (enExample) 2010-07-29

Family

ID=38657260

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009515748A Ceased JP2009541236A (ja) 2006-06-20 2007-06-15 組換えウイルスワクチン

Country Status (15)

Country Link
US (1) US20100129403A1 (enExample)
EP (1) EP2029169A2 (enExample)
JP (1) JP2009541236A (enExample)
KR (1) KR101141333B1 (enExample)
CN (1) CN101472610A (enExample)
AU (1) AU2007263281B2 (enExample)
BR (1) BRPI0713711A2 (enExample)
CA (1) CA2656266C (enExample)
CR (1) CR10571A (enExample)
IL (1) IL195683A0 (enExample)
MA (1) MA30581B1 (enExample)
MX (1) MX2008016036A (enExample)
NO (1) NO20090194L (enExample)
RU (1) RU2453335C2 (enExample)
WO (1) WO2007147529A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120052352A (ko) 2009-08-07 2012-05-23 트랜스진 에스.에이. Hbv 감염을 치료하는 조성물
US9216213B2 (en) * 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Hbv聚合酶突變體
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療c型肝炎病毒感染之療程(一)
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療c型肝炎病毒感染之療程(二)
CA2878800A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
CN103409451A (zh) * 2013-06-28 2013-11-27 扬州维克斯生物科技有限公司 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法
RU2695462C2 (ru) 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
DK3552615T3 (da) 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
EP3256156B1 (en) 2015-02-13 2025-02-12 Transgene Immunotherapeutic vaccine and antibody combination therapy
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
US20190330655A1 (en) 2016-12-28 2019-10-31 Transgene Sa Oncolytic viruses and therapeutic molecules
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
US20220290179A1 (en) 2019-08-29 2022-09-15 Astellas Pharma Inc. Genetically engineered oncolytic vaccinia viruses and methods of uses thereof
EP4178605A1 (en) 2020-07-13 2023-05-17 Transgene Treatment of immune depression
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
US20260015405A1 (en) 2022-07-01 2026-01-15 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
CN120380015A (zh) 2022-08-18 2025-07-25 特兰斯吉恩公司 嵌合痘病毒
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
EP0385630B1 (en) 1989-02-27 1996-11-27 Riker Laboratories, Inc. 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
TR200200797T2 (tr) 1999-09-25 2002-10-21 University Of Iowa Research Foundation İmmünostimülatör nükleik asitler
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
WO2002042480A2 (en) 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant
US20030139364A1 (en) 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2003080114A2 (en) 2002-03-19 2003-10-02 Powdermed Limited Imidazoquinoline adjuvants for vaccines
EP1660122A4 (en) 2003-08-25 2007-10-24 3M Innovative Properties Co IMMUNOSTIMULATORY COMBINATIONS AND TREATMENTS
WO2006042254A2 (en) 2004-10-08 2006-04-20 3M Innovative Properties Company Adjuvant for dna vaccines

Similar Documents

Publication Publication Date Title
JP2009541236A5 (enExample)
CA2656266A1 (en) Recombinant viral vaccine
RU2018116351A (ru) Пиримидиновое соединение
Patel et al. Novel drugs targeting Toll-like receptors for antiviral therapy
JP2007511546A5 (enExample)
JP2011529918A5 (enExample)
NL300899I2 (nl) Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit en Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie B01 eiwit
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
JP2012528892A5 (enExample)
JP2019513734A5 (enExample)
JP2012092103A5 (enExample)
JP2002541233A5 (enExample)
JP2008501000A5 (enExample)
JP2014521688A5 (enExample)
JP2006524669A5 (enExample)
JP2020500916A5 (enExample)
JP2016503029A5 (enExample)
JP2015512946A5 (enExample)
JP2013507423A5 (enExample)
JP2015533841A5 (enExample)
JP2002502874A5 (enExample)
JP2009523777A5 (enExample)
JP2011246469A5 (enExample)
JP2014518841A5 (enExample)
JP2012532883A5 (enExample)